WHAT A CONFERENCE! This was the brain child of Adrienne Dorrance and executed to perfection by an army of people including the amazing folks at Sundance Resort. Thank you to all our incredible attendees, speakers, and sponsors. We couldn’t have done this without all of you! #WBC2025

👉👉👉Please join us at the #ASCO25 #PlenarySession today for our group’s work on #Rusfertide #HepcidinMimetic Phase 3 Results #VERIFY for patients with Polycythemia Vera 📣 Andrew Kuykendall MD Naveen Pemmaraju, MD Kristen Pettit et al meetings.asco.org/abstracts-pres… #MPNSM ASCO

3rd Plenary #ASCO25: #VERIFY Ph III, Rufertide (subcutaneous, hepcidin mimetic) vs Placebo in phlebotomy dependent polycythemia vera. - Improved the need of phlebotomy. Hct control: 76.9% vs 32.9% - Improved symptoms/fatigue By: Drs. Andrew Kuykendall MD & Kathy Walsh, MD, MAEd

#ASCO25 #Plenary #VERIFY trial presented by Dr. Andrew Kuykendall. #Rusfertide (hepcidin mimetic); restores iron homeostasis in the bone marrow which is impaired in #PV. Study meets its primary endpoint: reduction in phlebotomies. Well tolerated with no significant AE’s.

👉👉👉Important presentation by Ruben A. Mesa, MD for #MPNSM field at #ASCO25 presenting the #SURPASS-ET study : Positive study for #RopegIFN for patients with high-risk randomized ph3 vs Anagrelide for patients intoler/resistant to prior HU in Essential Thrombocytosis | Lucia Masarova, MD ASCO

#ASCO25 Prof Andreas Hochhaus | #ASC4START #asciminib met its primary endpoint vs nilotinib in newly dx patients with CML #leusm ASCO

Early results show encouraging efficacy of a novel triplet combo of cladribine, venetoclax, and alternating azacitidine and low-dose cytarabine in patients with higher-risk MDS and CMML, presented by our Dr. Guillermo Montalban-Bravo at #ASCO25. Read more: bit.ly/43AMrN8 ASCO

Naveen Pemmaraju, MD updating at #ASCO25 PVEK (CD123-ADC) in BPDCN - CADENZA study High & durable response in 1L (de novo and PCHM):CR+CRc= 70% PCHM did not impact OS in 1L Half of 1L who received PVEK subsequently got SCT Good response also for R/R patients Manageable safety profile

Efficacy of erythroid-stimulating agent and luspatercept in VEXAS syndrome: A multicenter retrospective study by the FRENVEX group onlinelibrary.wiley.com/doi/10.1002/he…

#EHA2025 #EHA25 | Just arriving at European Hematology Association meeting - already starting with excellent, highly productive, intense discussions for future directions, future endpoints & thinking about novel mechanisms of #DiseaseModification for MPN field | #MPNSM Claire Harrison

Sustained benefits of rux+pelabresib over rux+placebo in 1L MF at week 72 in the phase 3 MANIFEST2 study. Especially good to see the difference between the arms in rates of leukemic transformation narrowing over time. #EHA25 #MPNSM

On Father’s Day, Mike Lee mocked a political shooting that left two children orphaned. State Rep. Melissa Hortman and her husband John were gunned down. Nov 7, 2028, Utah will replace him. Retweet if you’ve had enough. #UTpol #NoMoreLee #VoteThemOut

Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. news.abbvie.com/2025-06-16-Abb…

A lawmaker and her husband were shot. Their kids are now orphans. On Father’s Day, Sen. Mike Lee blamed the victims: “This is what happens when Marxists don’t get their way.” This is dangerous. It’s not who we are. He must be held accountable. #nomorelee #utpol

Shannon did not care much about winning Blackout in Bingo. Huntsman Cancer Institute

Happy Founder’s Week!! 💙💙💙

Please donate!!!!!

The Sri Sri Radha Krishna Temple near Spanish Fork has come under repeated gunfire in what temple leaders describe as acts of hate and domestic terrorism. sltrib.com/news/2025/06/3…

Congratulations to Drs. Oh and Young on their well deserved faculty promotions! 🥳@washudeptmed hematology.wustl.edu/congratulation…

Very proud of these two for having their work accepted for presentation at ISEH annual meeting! 🇯🇵🇯🇵🇯🇵